JP6764862B2 - 耐性細菌感染症の治療のための併用療法 - Google Patents

耐性細菌感染症の治療のための併用療法 Download PDF

Info

Publication number
JP6764862B2
JP6764862B2 JP2017526516A JP2017526516A JP6764862B2 JP 6764862 B2 JP6764862 B2 JP 6764862B2 JP 2017526516 A JP2017526516 A JP 2017526516A JP 2017526516 A JP2017526516 A JP 2017526516A JP 6764862 B2 JP6764862 B2 JP 6764862B2
Authority
JP
Japan
Prior art keywords
pharmaceutically acceptable
acceptable salt
sulbactam
compound
imipenem
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2017526516A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017533945A5 (cg-RX-API-DMAC7.html
JP2017533945A (ja
Inventor
デヨング，ブーデビーン・ロードウィック・マリア
デュランド−レヴィル，トーマス・フランソワ
フェルハイエン，イエルーン・キュネラ
トンマーシ，ルーベン
ミュラー，ジョン
Original Assignee
エンタシス・セラピューティックス・リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by エンタシス・セラピューティックス・リミテッド filed Critical エンタシス・セラピューティックス・リミテッド
Publication of JP2017533945A publication Critical patent/JP2017533945A/ja
Publication of JP2017533945A5 publication Critical patent/JP2017533945A5/ja
Application granted granted Critical
Publication of JP6764862B2 publication Critical patent/JP6764862B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2017526516A 2014-11-17 2015-11-17 耐性細菌感染症の治療のための併用療法 Active JP6764862B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462080667P 2014-11-17 2014-11-17
US62/080,667 2014-11-17
PCT/US2015/061076 WO2016081452A1 (en) 2014-11-17 2015-11-17 Combination therapy for treatment of resistant bacterial infections

Publications (3)

Publication Number Publication Date
JP2017533945A JP2017533945A (ja) 2017-11-16
JP2017533945A5 JP2017533945A5 (cg-RX-API-DMAC7.html) 2018-12-20
JP6764862B2 true JP6764862B2 (ja) 2020-10-07

Family

ID=54704148

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017526516A Active JP6764862B2 (ja) 2014-11-17 2015-11-17 耐性細菌感染症の治療のための併用療法

Country Status (31)

Country Link
US (2) US9968593B2 (cg-RX-API-DMAC7.html)
EP (1) EP3221313B1 (cg-RX-API-DMAC7.html)
JP (1) JP6764862B2 (cg-RX-API-DMAC7.html)
KR (1) KR102542392B1 (cg-RX-API-DMAC7.html)
CN (1) CN107108624B (cg-RX-API-DMAC7.html)
AU (1) AU2015350128B2 (cg-RX-API-DMAC7.html)
BR (1) BR112017010132B1 (cg-RX-API-DMAC7.html)
CA (1) CA2966632C (cg-RX-API-DMAC7.html)
CY (1) CY1121384T1 (cg-RX-API-DMAC7.html)
DK (1) DK3221313T3 (cg-RX-API-DMAC7.html)
EA (1) EA033829B1 (cg-RX-API-DMAC7.html)
ES (1) ES2717776T3 (cg-RX-API-DMAC7.html)
HK (1) HK1244798B (cg-RX-API-DMAC7.html)
HR (1) HRP20190580T1 (cg-RX-API-DMAC7.html)
HU (1) HUE044061T2 (cg-RX-API-DMAC7.html)
IL (1) IL251979B (cg-RX-API-DMAC7.html)
LT (1) LT3221313T (cg-RX-API-DMAC7.html)
ME (1) ME03357B (cg-RX-API-DMAC7.html)
MX (1) MX2017006383A (cg-RX-API-DMAC7.html)
MY (1) MY196240A (cg-RX-API-DMAC7.html)
PH (1) PH12017500852B1 (cg-RX-API-DMAC7.html)
PL (1) PL3221313T3 (cg-RX-API-DMAC7.html)
PT (1) PT3221313T (cg-RX-API-DMAC7.html)
RS (1) RS58429B1 (cg-RX-API-DMAC7.html)
SG (1) SG11201703633TA (cg-RX-API-DMAC7.html)
SI (1) SI3221313T1 (cg-RX-API-DMAC7.html)
SM (1) SMT201900187T1 (cg-RX-API-DMAC7.html)
TR (1) TR201905233T4 (cg-RX-API-DMAC7.html)
TW (1) TWI690317B (cg-RX-API-DMAC7.html)
WO (1) WO2016081452A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201703245B (cg-RX-API-DMAC7.html)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI690317B (zh) 2014-11-17 2020-04-11 英商安特西醫療有限公司 用於治療抗藥性細菌感染之組合療法
WO2017203266A1 (en) * 2016-05-25 2017-11-30 Entasis Therapeutics Limited Combination therapy for treatment of resistant bacterial infections
PT3512851T (pt) * 2016-09-16 2022-10-11 Entasis Therapeutics Ltd Compostos inibidores de beta-lactamase
EP3301094A1 (en) * 2016-09-30 2018-04-04 Mutabilis Heterocyclic compounds and their use in preventing or treating bacterial infections
EA202190617A3 (ru) * 2017-02-08 2021-10-29 Энтасис Терапеутикс Лимитед Соединения-ингибиторы бета-лактамаз
SMT202200110T1 (it) 2017-05-08 2022-05-12 Entasis Therapeutics Inc Composti e metodi per trattare infezioni batteriche
CN109422765B (zh) * 2017-09-05 2020-08-28 香港理工大学深圳研究院 C类β-内酰胺酶抑制剂及其制备方法和应用
US11660326B2 (en) * 2018-03-13 2023-05-30 Sepsia Therapeutics, S.L. Bacterial-binding peptides for treatment of infectious diseases and related inflammatory processes
FI3833665T3 (fi) 2018-08-09 2023-10-09 Antabio Sas Diatsabisyklo-oktanoneja seriini-beeta-laktamaasien inhibiittoreina
US11905286B2 (en) 2018-08-09 2024-02-20 Antabio Sas Diazabicyclooctanones as inhibitors of serine beta-lactamases
CN111658642A (zh) * 2019-03-05 2020-09-15 广州新创忆药物临床研究有限公司 一种治疗耐碳青霉烯类抗生素鲍曼不动杆菌感染的组合物
TWI715397B (zh) * 2019-12-31 2021-01-01 高雄榮民總醫院 根據領先標準將同儕數據繪製為圖表的方法、電腦程式產品及電腦可讀取媒體
BR112022018315A2 (pt) * 2020-04-02 2022-10-25 Glaxosmithkline Ip Dev Ltd Regime para tratar a infecção por neisseria gonorrhoeae com gepotidacina
CN117062598A (zh) * 2021-01-20 2023-11-14 恩塔西斯治疗有限公司 固定剂量抗生素组合物
WO2023206580A1 (en) * 2022-04-29 2023-11-02 Entasis Therapeutics Limited Durlobactam crystalline forms

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995018129A1 (en) 1993-12-29 1995-07-06 Pfizer Inc. Diazabicyclic neurokinin antagonists
FR2812635B1 (fr) 2000-08-01 2002-10-11 Aventis Pharma Sa Nouveaux composes heterocycliques, preparation et utilisation comme medicaments notamment comme anti- bacteriens
FR2825705B1 (fr) * 2001-06-08 2005-05-20 Aventis Pharma Sa Nouveaux composes heterocycliques, leur preparation et leur utilisation comme medicaments, notamment comme anti-bacteriens
FR2835186B1 (fr) 2002-01-28 2006-10-20 Aventis Pharma Sa Nouveaux composes heterocycliques, actifs comme inhibiteurs de beta-lactamases
US7439253B2 (en) 2002-12-06 2008-10-21 Novexel Heterocyclic compounds, their preparation and their use as medicaments, in particular as antibacterials and beta-lactamase inhibitors
FR2848210B1 (fr) * 2002-12-06 2007-10-19 Aventis Pharma Sa Nouveaux composes heterocycliques, leur preparation et leur utilisation comme medicaments, notamment comme anti-bacteriens et inhibiteurs de beta-lactamases
FR2914923B1 (fr) 2007-04-12 2013-06-14 Novexel Nouveaux composes heterocycliques azotes,leur preparation et leur utilisation comme medicaments antibacteriens.
ES2533826T3 (es) * 2008-01-18 2015-04-15 Merck Sharp & Dohme Corp. Inhibidores de beta-lactamasa
FR2930553B1 (fr) 2008-04-29 2010-05-21 Novexel Composes azabicycliques, leur preparation et leur utilisation comme medicaments, notamment inhibiteurs de beta-lactamases
EP3260551A1 (en) 2008-06-19 2017-12-27 Astra Zeneca Holding France Use of (1r,2s,5r) 1,6-diazabicyclo [3.2.1] octane-2-carboxamide, 7-oxo-6-(sulfooxy)-, monosodium salt as a diagnostic reagent for detecting serine beta-lactamases
FR2936798B1 (fr) 2008-10-03 2012-09-28 Novexel Nouveaux composes heterocycliques azotes, leur preparation et leur utilisation comme medicaments antibacteriens.
FR2936951B1 (fr) * 2008-10-10 2010-12-03 Novexel Nouvelles combinaisons de composes heterocycliques azotes antibacteriens avec d'autres composes antibacteriens et leur utilisation comme medicaments
FR2937034B1 (fr) 2008-10-10 2012-11-23 Novexel Nouveaux composes heterocycliques azotes, leur preparation et leur utilisation comme medicaments antibacteriens
FR2951171A1 (fr) 2009-10-09 2011-04-15 Novexel Nouveau sel de sodium d'un compose azabicyclique sous forme enantiomere cristallisee et nouvelles formes polymorphes et pseudopolymorphes ainsi que leur preparation
BR112013032770A2 (pt) * 2011-07-26 2017-02-07 Wockhardt Ltd composições farmacêuticas compreendendo antibiótico beta-lactama, sulbactama e inibidor de beta-lactamase
EP2736508A1 (en) 2011-07-26 2014-06-04 Wockhardt Limited Pharmaceutical compositions comprising sulbactam and beta-lactamase inhibitor
CA2833241C (en) 2011-08-27 2015-05-12 Wockhardt Limited 1,6-diazabicyclo [3,2,1] octan-7-one derivatives and their use in the treatment of bacterial infections
PT2872510T (pt) 2011-08-30 2017-03-01 Wockhardt Ltd Derivados de 1,6-diazabiciclo[3,2,1]octan-7-ona e seu uso no tratamento de infeções bacterianas
US8754102B2 (en) 2011-09-13 2014-06-17 Wockhardt Ltd. Nitrogen containing compounds and their use
US8796257B2 (en) 2011-12-02 2014-08-05 Naeja Pharmaceutical Inc. Bicyclic compounds and their use as antibacterial agents and β-lactamase inhibitors
US20150119363A1 (en) * 2012-02-15 2015-04-30 Rempex Pharmaceuticals, Inc.. Methods of treating bacterial infections
SG11201406120SA (en) 2012-03-30 2014-10-30 Cubist Pharm Inc ISOXAZOLE β-LACTAMASE INHIBITORS
US8969570B2 (en) 2012-03-30 2015-03-03 Cubist Pharmaceuticals, Inc. Beta-lactamase inhibitors
US8933233B2 (en) 2012-03-30 2015-01-13 Cubist Pharmaceuticals, Inc. 1,3,4-oxadiazole and 1,3,4-thiadiazole β-lactamase inhibitors
US8916709B2 (en) 2012-03-30 2014-12-23 Cubist Pharmaceuticals, Inc. 1,2,4-oxadiazole and 1,2,4-thiadiazole β-lactamase inhibitors
AR090539A1 (es) * 2012-04-02 2014-11-19 Astrazeneca Ab COMPUESTOS INHIBIDORES DE b LACTAMASA
MY174523A (en) 2012-05-30 2020-04-23 Meiji Seika Pharma Co Ltd ?-lactamase inhibitor and process for preparing the same
CA2881169C (en) 2012-08-25 2020-06-16 Wockhardt Limited 1,6-diazabicyclo [3,2,1]octan - 7 - one derivatives and their use in the treatment of bacterial infections
WO2014033561A1 (en) * 2012-09-03 2014-03-06 Wockhardt Limited Antibacterial compositions
CA2897446A1 (en) 2013-02-06 2014-08-14 Astrazeneca Ab Combination therapy for the treatment of nosocomial pneumonia
WO2014141132A1 (en) * 2013-03-14 2014-09-18 Naeja Pharmaceutical Inc. NEW HETEROCYCLIC COMPOUNDS AND THEIR USE AS ANTIBACTERIAL AGENTS AND β-LACTAMASE INHIBITORS
TWI690317B (zh) 2014-11-17 2020-04-11 英商安特西醫療有限公司 用於治療抗藥性細菌感染之組合療法

Also Published As

Publication number Publication date
PL3221313T3 (pl) 2019-07-31
SMT201900187T1 (it) 2019-05-10
AU2015350128B2 (en) 2019-05-16
DK3221313T3 (en) 2019-04-08
US10376499B2 (en) 2019-08-13
IL251979B (en) 2020-10-29
PH12017500852B1 (en) 2023-03-08
EA033829B1 (ru) 2019-11-29
EA201791069A1 (ru) 2017-11-30
SI3221313T1 (sl) 2019-04-30
HK1244798B (en) 2020-02-21
EP3221313B1 (en) 2019-01-09
US9968593B2 (en) 2018-05-15
CN107108624B (zh) 2020-01-07
US20180289681A1 (en) 2018-10-11
BR112017010132B1 (pt) 2023-02-14
BR112017010132A2 (pt) 2018-01-02
CN107108624A (zh) 2017-08-29
EP3221313A1 (en) 2017-09-27
TWI690317B (zh) 2020-04-11
KR102542392B1 (ko) 2023-06-09
TW201625234A (zh) 2016-07-16
MX2017006383A (es) 2017-08-21
US20180000800A1 (en) 2018-01-04
AU2015350128A1 (en) 2017-06-01
RS58429B1 (sr) 2019-04-30
LT3221313T (lt) 2019-03-25
CA2966632A1 (en) 2016-05-26
PH12017500852A1 (en) 2017-11-06
NZ731601A (en) 2024-02-23
CA2966632C (en) 2023-10-03
WO2016081452A1 (en) 2016-05-26
HUE044061T2 (hu) 2019-09-30
CY1121384T1 (el) 2020-05-29
ME03357B (me) 2019-10-20
PT3221313T (pt) 2019-04-15
HRP20190580T1 (hr) 2019-05-17
JP2017533945A (ja) 2017-11-16
IL251979A0 (en) 2017-06-29
ZA201703245B (en) 2019-08-28
MY196240A (en) 2023-03-24
KR20170082635A (ko) 2017-07-14
ES2717776T3 (es) 2019-06-25
SG11201703633TA (en) 2017-06-29
TR201905233T4 (tr) 2019-05-21

Similar Documents

Publication Publication Date Title
JP6764862B2 (ja) 耐性細菌感染症の治療のための併用療法
HK1244798A1 (en) Combination therapy for treatment of resistant bacterial infections
US9744160B2 (en) Pharmaceutical compositions comprising sulbactam and beta-lactamase inhibitor
WO2017203266A1 (en) Combination therapy for treatment of resistant bacterial infections
RU2593363C2 (ru) Композиции, включающие антибактериальное средство и тазобактам
US9789097B2 (en) Pharmaceutical compositions comprising antibacterial agents
US20170000775A1 (en) Pharmaceutical compositions comprising antibacterial agents
CN106029068A (zh) 包含抗菌剂的药物组合
US20150224168A1 (en) Combinations with a backbone-cyclized peptide
CN106659718A (zh) 包含抗菌剂的药物组合物
US20160287571A1 (en) Pharmaceutical compositions comprising antibacterial agents
US20170151221A1 (en) Pharmaceutical compositions comprising cefepime or sulbactam
WO2018193368A1 (en) Antibacterial compositions

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20181109

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20181109

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20191023

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200121

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20200121

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200219

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200518

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20200911

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20200914

R150 Certificate of patent or registration of utility model

Ref document number: 6764862

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250